Media Coverage

Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others. Take a look at the latest Evaluate and Vantage coverage.

If you have questions about Evaluate or require data and expert insights to help support your editorial content, please see our Media Contacts.

Latest Media Coverage

Nature Reviews Drug Discovery

The industry’s biggest drug launches

Pharma industry watchers will be familiar with the huge impact of the latest hepatitis C drugs, both medically and commercially. What might not be as clear is their…

Nature Reviews Drug Discovery

FDA new drug approvals in Q3 2018

With one full quarter still to go before the end of the year, 41 novel drugs have already been approved by the FDA, putting 2018 on track to surpass 1996’s record 53 new…

Browse the archive

Nature Reviews Drug Discovery

The industry’s biggest drug launches

Pharma industry watchers will be familiar with the huge impact of the latest hepatitis C drugs, both medically and commercially. What might not be as clear is their…

Nature Reviews Drug Discovery

FDA new drug approvals in Q3 2018

With one full quarter still to go before the end of the year, 41 novel drugs have already been approved by the FDA, putting 2018 on track to surpass 1996’s record 53 new…

The Pharma Letter

Look back at pharma news in week to October 26

Madeleine Armstrong on Vantage, the editorial arm of the Evaluate group, comments that, after the collapse of its lead project lirilumab last year, Innate Pharma has got…

PharmaLive

GlaxoSmithKline 2018: GSK’s next growth wave

EvaluatePharma’s 2018 World Preview report rated GSK2857916 as the pharma industry’s fifth most valuable R&D project with a net present value of nearly $7.5 billion.

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.